Esoform has been acquired by Ecolab
The family owners of Esoform have sold the company to Ecolab for an undisclosed consideration.
Esoform is active in the study, development, production and commercialization of disinfectants, infection prevention and personal care solutions. The company is a leading player in the Italian hospital market with a presence in pharmacies and the mass market.
Ecolab, based in the US, is the global leader in water, hygiene and energy technologies and services that provide and protect clean water, safe food, abundant energy and healthy environments. With this transaction Ecolab plans to expand its healthcare business into Europe, using the Esoform manufacturing plant as the production hub for the region.
Oaklins' team in Italy advised Esoform on the exit strategy and conducted negotiations with potential buyers throughout the transaction. Through a series of bids, the team optimized their proceeds and obtained a remarkable multiple from Ecolab.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more